Latest News

Biogen’s ‘positive’ Alzheimer’s trial has a problem with small numbers

Facing pressing questions about its latest clinical trial in Alzheimer’s disease, Biogen may have sowed further doubt on the future of an investigational treatment on Thursday.

At a medical conference in Spain, Biogen and partner Eisai presented data on the drug, BAN2401, meant to clear up concerns that its earlier observed benefits were a mirage. But the explanation revealed that BAN2401’s glimmer of promise is based on results from a small subset of patients in an otherwise large trial, which could be difficult to replicate in later studies.

Read the rest…

Source link

Related posts

New insights into the electrochemical behaviour of porous carbon electrodes for supercapacitors


FDA: Unapproved Ingredients in Many Supplements


Nordstrom Starts Selling $4 Reusable Cloth Face Masks Amid Pandemic


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World